PRESS RELEASE published on 09/11/2023 at 17:40, 2 years 11 months ago VALBIOTIS SA: Valbiotis présente les résultats complets de l’étude de Phase II/III REVERSE-IT : efficacité remarquable de TOTUM•63 contre le prédiabète et les stades précoces du diabète de type 2
PRESS RELEASE published on 09/06/2023 at 17:40, 2 years 11 months ago VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social - Juillet 2023
PRESS RELEASE published on 09/06/2023 at 17:40, 2 years 11 months ago VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social - Août 2023
PRESS RELEASE published on 08/04/2023 at 17:40, 3 years ago VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social - Juillet 2023
PRESS RELEASE published on 07/17/2023 at 17:40, 3 years 1 month ago VALBIOTIS SA: Bilan semestriel du contrat de liquidité
PRESS RELEASE published on 07/12/2023 at 17:40, 3 years 1 month ago Valbiotis announces its roadmap and strategic priorities on the eve of key milestones for its portfolio of innovative active substances
PRESS RELEASE published on 07/12/2023 at 17:40, 3 years 1 month ago Valbiotis annonce sa feuille de route et ses priorités stratégiques, à la veille d’étapes décisives pour son portefeuille de substances actives innovantes
PRESS RELEASE published on 07/03/2023 at 17:40, 3 years 1 month ago Valbiotis announces the appointment of Charlotte JEZEQUEL as Director of Human Relations and Executive Committee member
PRESS RELEASE published on 07/03/2023 at 17:40, 3 years 1 month ago Valbiotis annonce la nomination de Charlotte JEZEQUEL en tant que Directrice des Relations Humaines et son intégration au sein du Comité Exécutif
Published on 08/20/2026 at 02:22, 1 hour 57 minutes ago Infrastructure Sterilisation Drilling Begins at Tunkillia
Published on 08/20/2026 at 00:40, 3 hours 39 minutes ago Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program
Published on 08/19/2026 at 22:00, 6 hours 19 minutes ago Jaguar Health Reports Second Quarter 2026 Financials
Published on 08/19/2026 at 20:35, 7 hours 44 minutes ago Revive Therapeutics Announces Proposed Shares for Debt Settlement
Published on 08/20/2026 at 02:44, 1 hour 34 minutes ago Quarterly Report for Q2 and Interim Consolidated Financial Statements with Notes for the period from 1 January to 30 June 2026.
Published on 08/20/2026 at 01:45, 2 hours 34 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: 2026 Annual results – Delivers on guidance and progresses key strategic actions
Published on 08/18/2026 at 18:00, 1 day 10 hours ago KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 1 day 10 hours ago Mise à disposition du rapport financier annuel 2025-26
Published on 08/18/2026 at 11:15, 1 day 17 hours ago GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 10 au 14 août 2026
Published on 08/18/2026 at 11:15, 1 day 17 hours ago GUILLEMOT CORPORATION | Weekly report share buyback from August 10 to August 14 2026
Published on 08/17/2026 at 19:45, 2 days 8 hours ago Aéroports de Paris S.A - July 2026 traffic figures
